Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (1): 76-79.doi: 10.35541/cjd.20200060

• Reviews • Previous Articles     Next Articles

Interleukin-17A-mediated psoriasis and cardiovascular comorbidities

Zhao Ying, Wang Juanjuan, Ji Jiang, Su Wenxing, Wei Yuqian, Leng Hong, Ding Yujie, Shi Xin   

  1. Department of Dermatology and Venereology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
  • Received:2020-02-02 Revised:2020-08-02 Online:2022-01-15 Published:2021-12-31
  • Contact: Ji Jiang E-mail:jijiang2222@126.com
  • Supported by:
    National Natural Science Foundation of China （81803127）; Suzhou Min Sheng Technology Project （SS201643）; Suzhou Science and Technology Development Plan （SYS2018056）

PDF

45

PDF (Mobile)

0

Abstract: 【Abstract】 The interleukin （IL）-23/IL-17 axis is the main pathway in the pathogenesis of plaque-type psoriasis vulgaris, and IL-17A plays a key role in the relevant immune pathways. IL-17A mediates overlapping inflammatory pathways in atherosclerosis and psoriasis, promotes inflammation, coagulation and thrombosis, and plays an important role in the occurrence and development of cardiovascular comorbidities in patients with psoriasis. Inhibiting the inflammatory effect of IL-17A can reduce the incidence and mortality of cardiovascular comorbidities in patients with severe psoriasis. This review summarizes recent research progress in IL-17A-mediated systemic inflammation and cardiovascular comorbidities in patients with psoriasis, and provides a reference for prevention and reduction of cardiovascular comorbidities in patients with psoriasis in clinical practice.

Key words: Psoriasis, Interleukin-17, Cardiovascular diseases, Comorbidity, Interleukin-17A